Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: A post-hoc analysis of the PROLONG study

Cristina Legnani, Gualtiero Palareti, Benilde Cosmi, Michela Cini, Alberto Tosetto, Armando Tripodi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: The PROLONG study showed that patients with venous thromboembolism who had qualitatively abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The objective of this study was to evaluate the possible advantage of using quantitative D-dimer assays. Design and Methods: VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were performed in plasma aliquots sampled 30±10 days after cessation of vitamin K antagonism in 321 patients enrolled in the PROLONG study. Results: During the follow-up without vitamin K antagonism, 25 patients had recurrent venous thromboembolism. The cut-off levels of the quantitative assays giving results most comparable with those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS = 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients' age (≤70 vs. >70 years) was analyzed, it was found that only in younger patients was the rate of recurrence of venous thromboembolism significantly higher in patients with abnormal D-dimer levels. However, using the quantitative assays and age-specific cut-off levels it was possible to determine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200 ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest = 700 and 1000 ng/mL, in patients aged ≤70 and >70 years, respectively). Conclusions: Quantitative D-dimer assays may provide information useful for evaluating the individual risk of recurrent venous thromboembolism. They seem particularly advantageous since they allow the selection of different cut-off levels according to the age or other characteristics of the patients.

Original languageEnglish
Pages (from-to)900-907
Number of pages8
JournalHaematologica
Volume93
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Venous Thromboembolism
Recurrence
Vitamin K
fibrin fragment D

Keywords

  • Anticoagulation
  • D-dimer
  • Recurrence
  • Risk factors
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence : A post-hoc analysis of the PROLONG study. / Legnani, Cristina; Palareti, Gualtiero; Cosmi, Benilde; Cini, Michela; Tosetto, Alberto; Tripodi, Armando.

In: Haematologica, Vol. 93, No. 6, 06.2008, p. 900-907.

Research output: Contribution to journalArticle

Legnani, Cristina ; Palareti, Gualtiero ; Cosmi, Benilde ; Cini, Michela ; Tosetto, Alberto ; Tripodi, Armando. / Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence : A post-hoc analysis of the PROLONG study. In: Haematologica. 2008 ; Vol. 93, No. 6. pp. 900-907.
@article{2fde9a0782334cedb5464f9db0eb1484,
title = "Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: A post-hoc analysis of the PROLONG study",
abstract = "Background: The PROLONG study showed that patients with venous thromboembolism who had qualitatively abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The objective of this study was to evaluate the possible advantage of using quantitative D-dimer assays. Design and Methods: VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were performed in plasma aliquots sampled 30±10 days after cessation of vitamin K antagonism in 321 patients enrolled in the PROLONG study. Results: During the follow-up without vitamin K antagonism, 25 patients had recurrent venous thromboembolism. The cut-off levels of the quantitative assays giving results most comparable with those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS = 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients' age (≤70 vs. >70 years) was analyzed, it was found that only in younger patients was the rate of recurrence of venous thromboembolism significantly higher in patients with abnormal D-dimer levels. However, using the quantitative assays and age-specific cut-off levels it was possible to determine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200 ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest = 700 and 1000 ng/mL, in patients aged ≤70 and >70 years, respectively). Conclusions: Quantitative D-dimer assays may provide information useful for evaluating the individual risk of recurrent venous thromboembolism. They seem particularly advantageous since they allow the selection of different cut-off levels according to the age or other characteristics of the patients.",
keywords = "Anticoagulation, D-dimer, Recurrence, Risk factors, Venous thromboembolism",
author = "Cristina Legnani and Gualtiero Palareti and Benilde Cosmi and Michela Cini and Alberto Tosetto and Armando Tripodi",
year = "2008",
month = "6",
doi = "10.3324/haematol.12320",
language = "English",
volume = "93",
pages = "900--907",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence

T2 - A post-hoc analysis of the PROLONG study

AU - Legnani, Cristina

AU - Palareti, Gualtiero

AU - Cosmi, Benilde

AU - Cini, Michela

AU - Tosetto, Alberto

AU - Tripodi, Armando

PY - 2008/6

Y1 - 2008/6

N2 - Background: The PROLONG study showed that patients with venous thromboembolism who had qualitatively abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The objective of this study was to evaluate the possible advantage of using quantitative D-dimer assays. Design and Methods: VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were performed in plasma aliquots sampled 30±10 days after cessation of vitamin K antagonism in 321 patients enrolled in the PROLONG study. Results: During the follow-up without vitamin K antagonism, 25 patients had recurrent venous thromboembolism. The cut-off levels of the quantitative assays giving results most comparable with those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS = 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients' age (≤70 vs. >70 years) was analyzed, it was found that only in younger patients was the rate of recurrence of venous thromboembolism significantly higher in patients with abnormal D-dimer levels. However, using the quantitative assays and age-specific cut-off levels it was possible to determine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200 ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest = 700 and 1000 ng/mL, in patients aged ≤70 and >70 years, respectively). Conclusions: Quantitative D-dimer assays may provide information useful for evaluating the individual risk of recurrent venous thromboembolism. They seem particularly advantageous since they allow the selection of different cut-off levels according to the age or other characteristics of the patients.

AB - Background: The PROLONG study showed that patients with venous thromboembolism who had qualitatively abnormal results in a D-dimer assay (Clearview Simplify D-dimer) after discontinuation of vitamin K antagonism benefit from resumption of treatment with vitamin K antagonism. The objective of this study was to evaluate the possible advantage of using quantitative D-dimer assays. Design and Methods: VIDAS D-dimer Exclusion (bioMerieux), Innovance D-DIMER (Dade Behring), HemosIL D-dimer HS (Instrumentation Laboratory) and STA Liatest D-dimer (Diagnostica Stago) assays were performed in plasma aliquots sampled 30±10 days after cessation of vitamin K antagonism in 321 patients enrolled in the PROLONG study. Results: During the follow-up without vitamin K antagonism, 25 patients had recurrent venous thromboembolism. The cut-off levels of the quantitative assays giving results most comparable with those of the qualitative test were: VIDAS = 800 ng/mL; Innovance = 800 ng/mL; HemosIL HS = 300 ng/mL; STA Liatest = 700 ng/mL. When the effect of the patients' age (≤70 vs. >70 years) was analyzed, it was found that only in younger patients was the rate of recurrence of venous thromboembolism significantly higher in patients with abnormal D-dimer levels. However, using the quantitative assays and age-specific cut-off levels it was possible to determine statistically significant hazard ratios also in elderly patients (VIDAS = 600 and 1200 ng/mL, Innovance = 500 and 900 ng/mL, HemosIL HS = 250 and 450 ng/mL, STA Liatest = 700 and 1000 ng/mL, in patients aged ≤70 and >70 years, respectively). Conclusions: Quantitative D-dimer assays may provide information useful for evaluating the individual risk of recurrent venous thromboembolism. They seem particularly advantageous since they allow the selection of different cut-off levels according to the age or other characteristics of the patients.

KW - Anticoagulation

KW - D-dimer

KW - Recurrence

KW - Risk factors

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=44949178264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949178264&partnerID=8YFLogxK

U2 - 10.3324/haematol.12320

DO - 10.3324/haematol.12320

M3 - Article

C2 - 18443269

AN - SCOPUS:44949178264

VL - 93

SP - 900

EP - 907

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -